Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Your stomach will thank you later
Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, has gained attention for modest weight loss results in people seeking to shed 10 pounds or more
In the U.S., GLP-1 prescriptions more than doubled in just 18 months, topping nine million by early 2024
While the concept of GLP-1 microdosing is still being explored, the mechanism of GLP-1 drugs suggests how this dosing strategy might address common metabolic issues, and improve: Weight management and appetite control Energy consistency and fatigue reduction Insulin sensitivity While there are no primary clinical trials specifically designed to prove the long-term effectiveness of GLP-1 medication microdosing, the efficacy of low doses has been demonstrated within the full clinical trial data on dose-response relationships and titration phases: A years-long study of 2,405 patients that helped establish the efficacy of the current highest approved dose of semaglutide for weight loss found that lower doses still showed significant weight loss and appetite suppression compared to placebo
O.HaqueA
US$ 22.52
US$ 25.46
US$ 28.44
US$ 24.31
US$ 29.75
US$ 26.51
